STOCK TITAN
  1. Home
  2. Sec-filings
  3. SUPN
  4. [Form 4] Supernus Pharmaceuticals, Inc. Insider Trading Activity

Supernus (SUPN) Form 4: Director reduces stake to 46,307 shares

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Insider sale reported: Director Frederick M. Hudson sold 7,457 shares of Supernus Pharmaceuticals, Inc. (SUPN) on 08/14/2025 at a weighted-average price of $42.26 per share, with sale prices ranging from $42.14 to $42.37. After the transaction, Mr. Hudson beneficially owned 46,307 shares, reported as direct ownership. The Form 4 was signed on 08/18/2025 by an attorney-in-fact. The filing discloses only the non-derivative sale and provides an undertaking to supply detailed per-trade quantities and prices on request.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Director sold a modest block of shares; transaction is a routine disclosure without additional context on timing or intent.

The Form 4 documents a direct sale of 7,457 common shares by a company director at a weighted-average price of $42.26, leaving 46,307 shares beneficially owned. The filing is a standard Section 16 disclosure and includes a footnote that multiple trades occurred at prices between $42.14 and $42.37; the reporter offers to provide per-trade details if requested. No derivative transactions, option exercises, or amendments are disclosed. On its face, this is a routine insider sale rather than a corporate event.

TL;DR: A director-initiated sale was promptly reported; disclosure complies with Form 4 requirements and notes price range for multiple trades.

The filing identifies the reporting person as a director and indicates the Form 4 was filed by one reporting person. It specifies the sale date, weighted-average price, and remaining beneficial ownership, and it includes an explicit offer to provide breakdowns of the individual trade prices. There are no indications of related-party transactions, 10b5-1 plan checkboxes, or amendments attached to this filing. The disclosure meets routine SEC reporting expectations.

Insider Hudson Frederick M.
Role Director
Sold 7,457 shs ($315K)
Type Security Shares Price Value
Sale Common Stock 7,457 $42.26 $315K
Holdings After Transaction: Common Stock — 46,307 shares (Direct)
Footnotes (1)
  1. F1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.14 to $42.37. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Hudson Frederick M.
(Last) (First) (Middle)
C/O SUPERNUS PHARMACEUTICALS, INC.,
9715 KEY WEST AVENUE
(Street)
ROCKVILLE MD 20850
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
SUPERNUS PHARMACEUTICALS, INC. [ SUPN ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
08/14/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/14/2025 S 7,457 D $42.26(1) 46,307 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.14 to $42.37. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
Remarks:
/s/ Timothy C. Dec, as attorney-in-fact 08/18/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR